OCPWS
VRTX icon

One Charles Private Wealth Services’s Vertex Pharmaceuticals VRTX Stock Holding History

One Charles Private Wealth Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-767
Closed -$348K – 175
2025
Q4 		$348K Sell
767
-60
-7% -$25.9K 0.09% 116
2025
Q3 		$324K Buy
827
+123
+17% +$51.4K 0.09% 117
2025
Q2 		$313K Buy
+704
New +$324K 0.09% 114

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

One Charles Private Wealth Services's VRTX Position: Q1 2026 in Review

One Charles Private Wealth Services sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 767 shares — an estimated $348K sold.

One Charles Private Wealth Services first reported a position in VRTX in Q2 2025 and held it in 3 quarters. The position peaked at $348K in Q4 2025. 1,697 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • One Charles Private Wealth Services reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • One Charles Private Wealth Services sold 767 Vertex Pharmaceuticals shares in Q1 2026, an estimated $348K.
  • One Charles Private Wealth Services first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • One Charles Private Wealth Services's Vertex Pharmaceuticals position peaked at $348K in Q4 2025.
  • 1,697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on One Charles Private Wealth Services's 13F filing for Q1 2026, filed 7 May 2026.